Published in Cell Tissue Res on October 20, 2011
Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy. Curr Pharm Des (2013) 1.13
Biologics for tendon repair. Adv Drug Deliv Rev (2014) 1.09
Tendon and ligament regeneration and repair: clinical relevance and developmental paradigm. Birth Defects Res C Embryo Today (2013) 0.99
Restoration versus reconstruction: cellular mechanisms of skin, nerve and muscle regeneration compared. Regen Med Res (2013) 0.97
Skeletal muscle tissue engineering: methods to form skeletal myotubes and their applications. Tissue Eng Part B Rev (2014) 0.85
Cellular therapy in bone-tendon interface regeneration. Organogenesis (2013) 0.83
Textile cell-free scaffolds for in situ tissue engineering applications. J Mater Sci Mater Med (2016) 0.75
Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol (2005) 13.90
Socializing with the neighbors: stem cells and their niche. Cell (2004) 9.40
Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet (2006) 7.64
Hydrogels for tissue engineering. Chem Rev (2001) 7.25
Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science (2010) 6.67
Scaffolds in tissue engineering bone and cartilage. Biomaterials (2000) 6.11
Hypoxia-inducible factors, stem cells, and cancer. Cell (2007) 5.96
Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature (2010) 5.02
Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell (2010) 4.98
Designing materials to direct stem-cell fate. Nature (2009) 4.86
Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med (2007) 4.80
Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med (2011) 3.88
Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol (2011) 3.65
Nanotechnological strategies for engineering complex tissues. Nat Nanotechnol (2010) 3.15
Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. Aging Cell (2007) 2.70
Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev (2009) 2.57
miR-17, miR-19b, miR-20a, and miR-106a are down-regulated in human aging. Aging Cell (2010) 2.31
Management of articular cartilage defects of the knee. J Bone Joint Surg Am (2010) 2.01
Injectable matrices and scaffolds for drug delivery in tissue engineering. Adv Drug Deliv Rev (2007) 1.97
Mechanical signals as anabolic agents in bone. Nat Rev Rheumatol (2010) 1.95
Progeria syndromes and ageing: what is the connection? Nat Rev Mol Cell Biol (2010) 1.93
Inherited human diseases of heterotopic bone formation. Nat Rev Rheumatol (2010) 1.87
Hypoxia in static and dynamic 3D culture systems for tissue engineering of bone. Tissue Eng Part A (2008) 1.65
The use of percutaneous autologous bone marrow transplantation in nonunion and avascular necrosis of bone. J Bone Joint Surg Br (2005) 1.62
Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol (2010) 1.59
Angiogenic properties of aged adipose derived mesenchymal stem cells after hypoxic conditioning. J Transl Med (2011) 1.57
Insights into mesenchymal stem cell aging: involvement of antioxidant defense and actin cytoskeleton. Stem Cells (2009) 1.54
Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation. J Clin Invest (2010) 1.54
Nanosized hydroxyapatite and other calcium phosphates: chemistry of formation and application as drug and gene delivery agents. J Biomed Mater Res B Appl Biomater (2011) 1.53
Small RNAs: keeping stem cells in line. Cell (2008) 1.51
Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells Dev (2010) 1.50
ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J Bone Miner Res (2010) 1.49
Fracture healing is accelerated in the absence of the adaptive immune system. J Bone Miner Res (2011) 1.46
Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res (2010) 1.41
BMPs: from bone to body morphogenetic proteins. Sci Signal (2010) 1.41
Silk fibroin as a vehicle for drug delivery applications. J Control Release (2010) 1.40
Signal transduction pathways involved in mechanotransduction in bone cells. Biochem Biophys Res Commun (2006) 1.40
Homing of endogenous stem/progenitor cells for in situ tissue regeneration: Promises, strategies, and translational perspectives. Biomaterials (2011) 1.35
Mesenchymal stem cells and bone regeneration: current status. Injury (2011) 1.34
Mesenchymal stromal cell therapy: a revolution in Regenerative Medicine? Bone Marrow Transplant (2011) 1.33
Adhesion molecules in the stem cell niche--more than just staying in shape? J Cell Sci (2010) 1.31
A review on endogenous regenerative technology in periodontal regenerative medicine. Biomaterials (2010) 1.31
Novel modulators of senescence, aging, and longevity: Small non-coding RNAs enter the stage. Exp Gerontol (2010) 1.28
Early temporary porosis of bone induced by internal fixation implants. A reaction to necrosis, not to stress protection? Clin Orthop Relat Res (1988) 1.27
Epigenetic regulation of aging stem cells. Oncogene (2011) 1.26
The effect of age on the efficacy of human mesenchymal stem cell transplantation after a myocardial infarction. Rejuvenation Res (2010) 1.25
Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise. J Bone Miner Res (2005) 1.23
BMP-silk composite matrices heal critically sized femoral defects. Bone (2007) 1.22
Generation and transplantation of an autologous vascularized bioartificial human tissue. Transplantation (2009) 1.21
Rescuing replication and osteogenesis of aged mesenchymal stem cells by exposure to a young extracellular matrix. FASEB J (2011) 1.19
Knockdown of p21(Cip1/Waf1) enhances proliferation, the expression of stemness markers, and osteogenic potential in human mesenchymal stem cells. Aging Cell (2011) 1.17
Tendon tissue engineering: adipose-derived stem cell and GDF-5 mediated regeneration using electrospun matrix systems. Biomed Mater (2011) 1.17
Concise review: adipose-derived stromal cells for skeletal regenerative medicine. Stem Cells (2011) 1.16
Degradable polyester scaffolds with controlled surface chemistry combining minimal protein adsorption with specific bioactivation. Nat Mater (2011) 1.15
Rapid uptake of gold nanorods by primary human blood phagocytes and immunomodulatory effects of surface chemistry. ACS Nano (2010) 1.13
Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mesenchymal stem cells. Transplantation (2011) 1.10
Regenerative medicine of the trachea: the first human case. Ann Otol Rhinol Laryngol (2005) 1.09
Bioprinting of hybrid tissue constructs with tailorable mechanical properties. Biofabrication (2011) 1.08
Toward modeling the bone marrow niche using scaffold-based 3D culture systems. Biomaterials (2010) 1.07
Long bone defect models for tissue engineering applications: criteria for choice. Tissue Eng Part B Rev (2010) 1.06
Testing the critical size in calvarial bone defects: revisiting the concept of a critical-size defect. Plast Reconstr Surg (2010) 1.06
Microarray analyses of transdifferentiated mesenchymal stem cells. J Cell Biochem (2008) 1.06
Engineering a stem cell house into a home. Stem Cell Res Ther (2011) 1.04
Effect of aging on cellular mechanotransduction. Ageing Res Rev (2009) 1.04
Optimization strategies for electrospun silk fibroin tissue engineering scaffolds. Biomaterials (2009) 1.03
GFP chimeric models exhibited a biphasic pattern of mesenchymal cell invasion in tendon healing. J Cell Physiol (2007) 1.03
Combined 3D and hypoxic culture improves cartilage-specific gene expression in human chondrocytes. Acta Orthop (2011) 1.03
State of the art and future perspectives of articular cartilage regeneration: a focus on adipose-derived stem cells and platelet-derived products. J Tissue Eng Regen Med (2011) 1.03
Disruption of the Fgf2 gene activates the adipogenic and suppresses the osteogenic program in mesenchymal marrow stromal stem cells. Bone (2010) 1.02
Effects of myostatin deletion in aging mice. Aging Cell (2009) 1.02
A histological evaluation for guided bone regeneration induced by a collagenous membrane. Biomaterials (2005) 1.02
A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. Endocrinology (2010) 1.01
Estrogen receptor and Wnt signaling interact to regulate early gene expression in response to mechanical strain in osteoblastic cells. Biochem Biophys Res Commun (2010) 1.01
Hypoxic preconditioning of human mesenchymal stem cells overcomes hypoxia-induced inhibition of osteogenic differentiation. Tissue Eng Part A (2010) 1.01
Establishment of immortalized periodontal ligament progenitor cell line and its behavioural analysis on smooth and rough titanium surface. Eur Cell Mater (2010) 1.00
Rodent models in bone-related research: the relevance of calvarial defects in the assessment of bone regeneration strategies. Lab Anim (2010) 0.99
Extracellular matrix-mimetic adhesive biomaterials for bone repair. J Biomed Mater Res A (2010) 0.99
The axolotl model for regeneration and aging research: a mini-review. Gerontology (2011) 0.98
Mesenchymal stem cells in the treatment of autoimmune diseases. Ann Rheum Dis (2010) 0.97
Secretion of angiogenic proteins by human multipotent mesenchymal stromal cells and their clinical potential in the treatment of avascular osteonecrosis. Leukemia (2008) 0.97
Stem cell microenvironments--unveiling the secret of how stem cell fate is defined. Macromol Biosci (2010) 0.97
The skeletal responsiveness to mechanical loading is enhanced in mice with a null mutation in estrogen receptor-beta. Am J Physiol Endocrinol Metab (2007) 0.97
What we should know before using tissue engineering techniques to repair injured tendons: a developmental biology perspective. Tissue Eng Part B Rev (2011) 0.97
Low oxygen tension is a more potent promoter of chondrogenic differentiation than dynamic compression. J Biomech (2010) 0.96
Injectable poly(lactic-co-glycolic) acid scaffolds with in situ pore formation for tissue engineering. Acta Biomater (2009) 0.95
Osteocyte primary cilium and its role in bone mechanotransduction. Ann N Y Acad Sci (2010) 0.95
Silk fibroin/hyaluronan scaffolds for human mesenchymal stem cell culture in tissue engineering. Biomaterials (2009) 0.95
Enhanced proliferation capacity of porcine tenocytes in low O2 tension culture. Biotechnol Lett (2009) 0.94
Bone mineral content and density in the humerus of adult myostatin-deficient mice. Calcif Tissue Int (2002) 0.94
[Cell based therapy for the treatment of femoral head necrosis]. Orthopade (2007) 0.94
In vitro platforms for tissue engineering: implications for basic research and clinical translation. J Tissue Eng Regen Med (2011) 0.92
Emerging ideas: treatment of precollapse osteonecrosis using stem cells and growth factors. Clin Orthop Relat Res (2010) 0.92
Human blood and marrow side population stem cell and Stro-1 positive bone marrow stromal cell numbers decline with age, with an increase in quality of surviving stem cells: correlation with cytokines. Mech Ageing Dev (2010) 0.91
Phases 1-3 clinical trials using adult stem cells in osteonecrosis and nonunion fractures. Stem Cells Int (2010) 0.90
Investigational anabolic therapies for osteoporosis. Expert Opin Investig Drugs (2010) 0.90
Identification of microRNAs regulated by activin A in human embryonic stem cells. J Cell Biochem (2010) 0.89
Cell therapy for secondary osteonecrosis of the femoral condyles using the Cellect DBM System: a preliminary report. J Arthroplasty (2008) 0.89
Tissue engineering solutions for tendon repair. J Am Acad Orthop Surg (2011) 0.88
The use of sulfonated silk fibroin derivatives to control binding, delivery and potency of FGF-2 in tissue regeneration. Biomaterials (2009) 0.88
Biopolymer-based growth factor delivery for tissue repair: from natural concepts to engineered systems. Tissue Eng Part B Rev (2009) 0.87
Integrin-linked kinase (ILK) is required for polarizing the epiblast, cell adhesion, and controlling actin accumulation. Genes Dev (2003) 2.68
Conversion of human bone marrow-derived mesenchymal stem cells into tendon progenitor cells by ectopic expression of scleraxis. Stem Cells Dev (2011) 1.91
Major biological obstacles for persistent cell-based regeneration of articular cartilage. Arthritis Res Ther (2007) 1.85
Silk microspheres for encapsulation and controlled release. J Control Release (2006) 1.81
The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors. PLoS One (2012) 1.76
Growth factor gradients via microsphere delivery in biopolymer scaffolds for osteochondral tissue engineering. J Control Release (2008) 1.72
Human mesenchymal stem cells in contact with their environment: surface characteristics and the integrin system. J Cell Mol Med (2007) 1.69
Porous silk fibroin 3-D scaffolds for delivery of bone morphogenetic protein-2 in vitro and in vivo. J Biomed Mater Res A (2006) 1.68
Hypoxia in static and dynamic 3D culture systems for tissue engineering of bone. Tissue Eng Part A (2008) 1.65
Primary malignant sarcomas of the heart and great vessels in adult patients--a single-center experience. Oncologist (2007) 1.63
Bone morphogenetic protein-2 decorated silk fibroin films induce osteogenic differentiation of human bone marrow stromal cells. J Biomed Mater Res A (2004) 1.59
Control of in vitro tissue-engineered bone-like structures using human mesenchymal stem cells and porous silk scaffolds. Biomaterials (2006) 1.56
25th anniversary article: Engineering hydrogels for biofabrication. Adv Mater (2013) 1.54
Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res (2005) 1.53
Cartilage-like tissue engineering using silk scaffolds and mesenchymal stem cells. Tissue Eng (2006) 1.45
Researching into the cellular shape, volume and elasticity of mesenchymal stem cells, osteoblasts and osteosarcoma cells by atomic force microscopy. J Cell Mol Med (2008) 1.40
Silk fibroin as a vehicle for drug delivery applications. J Control Release (2010) 1.40
How smart do biomaterials need to be? A translational science and clinical point of view. Adv Drug Deliv Rev (2012) 1.38
Silk fibroin spheres as a platform for controlled drug delivery. J Control Release (2008) 1.35
Human mesenchymal progenitor cell-based tissue engineering of a single-unit osteochondral construct. Tissue Eng (2004) 1.34
Hypertrophy is induced during the in vitro chondrogenic differentiation of human mesenchymal stem cells by bone morphogenetic protein-2 and bone morphogenetic protein-4 gene transfer. Arthritis Res Ther (2009) 1.34
Introducing a single-cell-derived human mesenchymal stem cell line expressing hTERT after lentiviral gene transfer. J Cell Mol Med (2008) 1.31
Hydroxyapatite scaffolds for bone tissue engineering made by 3D printing. J Mater Sci Mater Med (2005) 1.30
Localized delivery of growth factors for bone repair. Eur J Pharm Biopharm (2004) 1.30
Effect of scaffold design on bone morphology in vitro. Tissue Eng (2006) 1.28
Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence--a multi-centre study. J Craniomaxillofac Surg (2010) 1.28
Nondestructive micro-computed tomography for biological imaging and quantification of scaffold-bone interaction in vivo. Biomaterials (2007) 1.24
Morphological and immunocytochemical characteristics indicate the yield of early progenitors and represent a quality control for human mesenchymal stem cell culturing. J Anat (2009) 1.24
Plasticity in adipogenesis and osteogenesis of human mesenchymal stem cells. Mol Cell Endocrinol (2007) 1.22
Tissue engineering for bone defect healing: an update on a multi-component approach. Injury (2008) 1.22
Concise review: the clinical application of mesenchymal stem cells for musculoskeletal regeneration: current status and perspectives. Stem Cells Transl Med (2012) 1.19
Silk fibroin matrices for the controlled release of nerve growth factor (NGF). Biomaterials (2007) 1.17
Phagocytosis independent extracellular nanoparticle clearance by human immune cells. Nano Lett (2010) 1.17
Iron oxide labelling of human mesenchymal stem cells in collagen hydrogels for articular cartilage repair. Biomaterials (2007) 1.16
Degradable polyester scaffolds with controlled surface chemistry combining minimal protein adsorption with specific bioactivation. Nat Mater (2011) 1.15
Biofunctionalized polymer surfaces exhibiting minimal interaction towards immobilized proteins. Chemphyschem (2004) 1.14
Polychrome labeling of bone with seven different fluorochromes: enhancing fluorochrome discrimination by spectral image analysis. Bone (2005) 1.14
Synthesis, patterning and applications of star-shaped poly(ethylene glycol) biofunctionalized surfaces. Mol Biosyst (2007) 1.13
Reduced postoperative pain in total hip arthroplasty after minimal-invasive anterior approach. Int Orthop (2011) 1.13
Rapid uptake of gold nanorods by primary human blood phagocytes and immunomodulatory effects of surface chemistry. ACS Nano (2010) 1.13
Insulin-like growth factor I releasing silk fibroin scaffolds induce chondrogenic differentiation of human mesenchymal stem cells. J Control Release (2007) 1.12
Desmoplastic fibroma: a case report with three years of clinical and radiographic observation and review of the literature. Open Orthop J (2013) 1.11
Human mesenchymal stem cells at the single-cell level: simultaneous seven-colour immunofluorescence. J Anat (2007) 1.10
Flexible intramedullary nailing for stabilization of displaced midshaft clavicle fractures: technique and results in 87 patients. Acta Orthop (2007) 1.08
Mesenchymal stem cell characteristics of human anterior cruciate ligament outgrowth cells. Tissue Eng Part A (2011) 1.08
Concepts in gene therapy for cartilage repair. Injury (2008) 1.08
BMP12 and BMP13 gene transfer induce ligamentogenic differentiation in mesenchymal progenitor and anterior cruciate ligament cells. Cytotherapy (2010) 1.06
Silk coatings on PLGA and alginate microspheres for protein delivery. Biomaterials (2007) 1.06
IKK-2 is required for TNF-alpha-induced invasion and proliferation of human mesenchymal stem cells. J Mol Med (Berl) (2008) 1.06
Uncovering the cellular and molecular changes in tendon stem/progenitor cells attributed to tendon aging and degeneration. Aging Cell (2013) 1.05
Chondrogenic differentiation of mesenchymal progenitor cells encapsulated in ultrahigh-viscosity alginate. J Orthop Res (2003) 1.05
Raman spectroscopy for the non-contact and non-destructive monitoring of collagen damage within tissues. J Biophotonics (2011) 1.03
Local tenomodulin absence, angiogenesis, and matrix metalloproteinase activation are associated with the rupture of the chordae tendineae cordis. Circulation (2008) 1.03
Optimization strategies for electrospun silk fibroin tissue engineering scaffolds. Biomaterials (2009) 1.03
Effects of high glucose on mesenchymal stem cell proliferation and differentiation. Biochem Biophys Res Commun (2007) 1.02
Enhanced in vitro chondrogenesis of primary mesenchymal stem cells by combined gene transfer. Tissue Eng Part A (2009) 1.02
Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg (2010) 1.02
Estrogen receptor and Wnt signaling interact to regulate early gene expression in response to mechanical strain in osteoblastic cells. Biochem Biophys Res Commun (2010) 1.01
Effects of chondrogenic and osteogenic regulatory factors on composite constructs grown using human mesenchymal stem cells, silk scaffolds and bioreactors. J R Soc Interface (2008) 1.01
Hypoxic preconditioning of human mesenchymal stem cells overcomes hypoxia-induced inhibition of osteogenic differentiation. Tissue Eng Part A (2010) 1.01
Nonviral genetic modification mediates effective transgene expression and functional RNA interference in human mesenchymal stem cells. J Gene Med (2005) 1.01
Direct 3D powder printing of biphasic calcium phosphate scaffolds for substitution of complex bone defects. Biofabrication (2014) 0.99
Effect of collagen I and fibronectin on the adhesion, elasticity and cytoskeletal organization of prostate cancer cells. Biochem Biophys Res Commun (2010) 0.99
Stem cell- and growth factor-based regenerative therapies for avascular necrosis of the femoral head. Stem Cell Res Ther (2012) 0.99
Quantitative polymerase chain reaction as a reliable method to determine functional lentiviral titer after ex vivo gene transfer in human mesenchymal stem cells. J Gene Med (2007) 0.99
FGF23 is a putative marker for bone healing and regeneration. J Orthop Res (2009) 0.98
Peptide-functionalized gold nanorods increase liver injury in hepatitis. ACS Nano (2012) 0.98
Microporous silk fibroin scaffolds embedding PLGA microparticles for controlled growth factor delivery in tissue engineering. Biomaterials (2009) 0.98
Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett (2009) 0.97
Stem cell microenvironments--unveiling the secret of how stem cell fate is defined. Macromol Biosci (2010) 0.97
The physiological performance of a three-dimensional model that mimics the microenvironment of the small intestine. Biomaterials (2011) 0.97
Increased stemness and migration of human mesenchymal stem cells in hypoxia is associated with altered integrin expression. Biochem Biophys Res Commun (2012) 0.97
First inducible transgene expression in porcine large animal models. FASEB J (2011) 0.96
Validation of a femoral critical size defect model for orthotopic evaluation of bone healing: a biomechanical, veterinary and trauma surgical perspective. Tissue Eng Part C Methods (2008) 0.96
Vascularised human tissue models: a new approach for the refinement of biomedical research. J Biotechnol (2010) 0.96
Solid-supported lipid bilayers to drive stem cell fate and tissue architecture using periosteum derived progenitor cells. Biomaterials (2012) 0.96
Myoblast morphology and organization on biochemically micro-patterned hydrogel coatings under cyclic mechanical strain. Biomaterials (2009) 0.96
Indian hedgehog gene transfer is a chondrogenic inducer of human mesenchymal stem cells. Arthritis Res Ther (2012) 0.95
Impact of indium-111 oxine labelling on viability of human mesenchymal stem cells in vitro, and 3D cell-tracking using SPECT/CT in vivo. Mol Imaging Biol (2011) 0.95
Silk fibroin/hyaluronan scaffolds for human mesenchymal stem cell culture in tissue engineering. Biomaterials (2009) 0.95
Immobilized DNA aptamers used as potent attractors for porcine endothelial precursor cells. J Biomed Mater Res A (2008) 0.94
Electrospun matrices for localized drug delivery: current technologies and selected biomedical applications. Eur J Pharm Biopharm (2012) 0.94
Customised osteotomy guides and endoprosthetic reconstruction for periacetabular tumours. Int Orthop (2014) 0.93
Differentiation of individual human mesenchymal stem cells probed by FTIR microscopic imaging. Analyst (2007) 0.92
Non-invasive time-lapsed monitoring and quantification of engineered bone-like tissue. Ann Biomed Eng (2007) 0.91